MRKT Call: An Unbothered S&P 500
RiskReversal Pod
00:00
Pfizer Charts
Pfizer has its own issues clearly you know they their pipeline is probably if you measure them up against some of their competitors I mean they're nowhere near where they should be. They sold their consumer products business 12 13 years ago to Johnson and Johnson for about 16 billion dollars which seemed like a score at the time but it proved to be a score for J&J. The broader market is doing all right can these guys pull up a Pfizer chart here because this one is pretty fascinating, Dan says.
Play episode from 24:58
Transcript
